NYSE:ENZ - Enzo Biochem Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$4.06 +0.06 (+1.50 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$4.00
Today's Range$4.01 - $4.11
52-Week Range$3.95 - $11.50
Volume49,978 shs
Average Volume167,297 shs
Market Capitalization$195.27 million
P/E RatioN/A
Dividend YieldN/A
Enzo Biochem logoEnzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 29 patient service centers in New York and New Jersey; and a free standing ?STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories


Debt-to-Equity RatioN/A
Current Ratio4.63
Quick Ratio4.24


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$107.80 million
Price / Sales1.78
Cash Flow$0.0229 per share
Price / Cash176.91
Book Value$1.91 per share
Price / Book2.13


EPS (Most Recent Fiscal Year)N/A
Net Income$-2,500,000.00
Net Margins-4.12%
Return on Equity-6.31%
Return on Assets-5.16%


Outstanding Shares47,170,000
Market Cap$195.27 million

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) announced its quarterly earnings data on Tuesday, June, 12th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. The medical research company had revenue of $25.63 million for the quarter. Enzo Biochem had a negative net margin of 4.12% and a negative return on equity of 6.31%. View Enzo Biochem's Earnings History.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release their next quarterly earnings announcement on Wednesday, September, 26th 2018. View Earnings Estimates for Enzo Biochem.

Who are some of Enzo Biochem's key competitors?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:
  • Dr. Elazar Rabbani Ph.D., Co-Founder, Chairman, CEO & Sec. (Age 75)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 68)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 52)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 60)
  • Dr. Dieter Schapfel, Chief Medical Director (Age 55)

Has Enzo Biochem been receiving favorable news coverage?

News coverage about ENZ stock has trended somewhat negative this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Enzo Biochem earned a daily sentiment score of 0.00 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 48.58 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Enzo Biochem.

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Evermore Global Advisors LLC (10.07%), BlackRock Inc. (8.47%), Renaissance Technologies LLC (6.36%), Dimensional Fund Advisors LP (4.25%), Gilder Gagnon Howe & Co. LLC (1.62%) and Acadian Asset Management LLC (1.02%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Institutional Ownership Trends for Enzo Biochem.

Which institutional investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Gilder Gagnon Howe & Co. LLC, Kopp Investment Advisors LLC, First Light Asset Management LLC, Evermore Global Advisors LLC, GSA Capital Partners LLP, Russell Investments Group Ltd. and ClariVest Asset Management LLC. Company insiders that have sold Enzo Biochem company stock in the last year include Barry W Weiner, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Insider Buying and Selling for Enzo Biochem.

Which institutional investors are buying Enzo Biochem stock?

ENZ stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Algert Global LLC, Alps Advisors Inc., Alps Advisors Inc., Alps Advisors Inc. and Berson & Corrado Investment Advisors LLC. View Insider Buying and Selling for Enzo Biochem.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $4.07.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $195.27 million and generates $107.80 million in revenue each year. Enzo Biochem employs 472 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave, New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.

MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.